Aleksei Emelianov

Dr. Aleksei Emelianov

Sechenov First Moscow State Medical University (Sechenov University), Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YBYuri Belenkov
Yuri Belenkov
AAAnton Ageev
Anton Ageev
MKMaria Kozhevnikova
Maria Kozhevnikova
NKNatalia Khabarova
Natalia Khabarova
AKAnastasia Krivova
Anastasia Krivova
EPElena Privalova
Elena Privalova
Background: Progressive myocardial remodeling (MR) in chronic heart failure (CHF) leads to aggravation of systolic dysfunction (SD) and clinical manifestations. Identification of metabolomic markers of these processes may help in the search for new therapeutic approaches aimed at achieving reversibility of MR and improving prognosis in patients with CHF. Methods: To determine the relationship between plasma acylcarnitine (ACs) levels, MR parameters and clinical characteristics, in patients with CHF of ischemic etiology (n = 79) and patients with coronary heart disease CHD (n = 19) targeted analysis of 30 ACs was performed by flow injection analysis mass spectrometry. Results: Significant differences between cohorts were found for the levels of 11 ACs. Significant positive correlations (r > 0.3) between the medium- and long-chain ACs (MCACs and LCACs) and symptoms (CHF NYHA functional class (FC); r = 0.31−0.39; p < 0.05); negative correlation (r = −0.31−0.34; p < 0.05) between C5-OH and FC was revealed. Positive correlations of MCACs and LCACs (r = 0.31−0.48; p < 0.05) with the left atrium size and volume, the right atrium volume, right ventricle, and the inferior vena cava sizes, as well as the pulmonary artery systolic pressure level were shown. A negative correlation between C18:1 and left ventricular ejection fraction (r = −0.31; p < 0.05) was found. However, a decrease in levels compared to referent values of ACs with medium and long chain lengths was 50% of the CHF-CHD cohort. Carnitine deficiency was found in 6% and acylcarnitine deficiency in 3% of all patients with chronic heart disease. Conclusions: ACs may be used in assessing the severity of the clinical manifestations and MR. ACs are an important locus to study in terms of altered metabolic pathways in patients with CHF of ischemic etiology and SD. Further larger prospective trials are warranted and needed to determine the potential benefits to treat patients with CV diseases with aberrate AC levels.

17 September 2025 in Carbon
Verified
Journal Article
Open access
GDGour Mohan Das
Gour Mohan Das
EHEero Hulkko
Eero Hulkko
AEAleksei Emelianov
Aleksei Emelianov
MSMarc Garriga Santiveri
Marc Garriga Santiveri
PMPasi Myllyperkiö
Pasi Myllyperkiö
MPMika Pettersson
Mika Pettersson

24 January 2024 in Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
EMEmel’yanov
Emel’yanov
AEAleksei Emelianov
Aleksei Emelianov
EZE. A. Zheleznykh
E. A. Zheleznykh
MKM. V. Kozhevnikova
M. V. Kozhevnikova
VZV. Yu. Zektser
V. Yu. Zektser
YBYu. N. Belenkov
Yu. N. Belenkov

26 June 2023 in Digital Diagnostics
Verified
Journal Article
Open access
PDF file
AEAleksei Emelianov
Aleksei Emelianov
EZElena A. Zheleznykh
Elena A. Zheleznykh
MKMaria Kozhevnikova
Maria Kozhevnikova
AAAnton Ageev
Anton Ageev
VZVita Y. Zektser
Vita Y. Zektser
YBYuri Belenkov
Yuri Belenkov
BACKGROUND: Chronic heart failure (CHF) is one of the leading causes of death. Telemedicine and remote monitoring (RM) are a way to increase life expectancy and quality of life in patients with CHF. Methods based on messengers familiar to patients promote adherence and do not require additional training. AIM: To compare quality of life and adherence to therapy in patients with CHF who were on RM using a chatbot compared to the standard follow-up (SFU) group for 3 months. METHODS: Patients with CHF on optimal drug therapy discharged from the hospital were included in the study. Comparison groups were formed according to the method of observation, particularly, RM and SFU. A chatbot was set up for patients in the RM group. Monitoring was done using a seven-question survey sent daily. The signs of decompensation (red flags [RF]) were increased edema, dyspnea, body weight 2 kg per week, and changes in individual parameters of heart rate and blood pressure. If a RF was detected, telephone contact was made, and the therapy was corrected if necessary. Quality of life was assessed according to the Minnesota Quality of Life Questionnaire for patients with CHF (highest, 0 points; lowest, 105 points), and adherence was assessed using the Adherence Scale of the National Society for Evidence-based Pharmacotherapy. RESULTS: A total of 60 patients were included in the study; 37 patients completed a 3-month follow-up. The RM group (n=17, 13 men, 76.5%; median age 61 [51; 62]) and comparison group (n=20, 14 men, 70%; mean age 64.98.9) were comparable according to the functional class (New York Heart Association), but differed in ejection fraction (42.813% versus 53.210.4% [p 0.05]). Adherence to the chat-bot was 67.2%. Adherence to therapy was not significantly different between the RM and SFU groups accounting for (17 [100%]) and (18 [90%], respectively, (p=0.62). In the RM group, RF was detected in 7 (41%) patients. Only one patient required correction of therapy. Patients in the RM group required no referral to a medical facility, whereas 2 patients in the SFU group required medical care. Quality of life was statistically significantly higher in the RM group, reaching 28.713.9 points compared to 37.717.9 points in the SFU group (p=0.04). CONCLUSIONS: After 3 months, patients in the RM group were committed to the chatbot, with adherence to therapy comparable to the SFU group. Quality of life was statistically significantly higher in the RM group. Patients in the RM group did not go to medical facilities, in contrast to the SFU group. The limitations of the study were the small sample size and short follow-up period. The results require further research to obtain additional data.

5 November 2024 in Digital Diagnostics
Verified
Journal Article
Open access
PDF file
AEAleksei Emelianov
Aleksei Emelianov
MKMaria Kozhevnikova
Maria Kozhevnikova
EZElena A. Zheleznykh
Elena A. Zheleznykh
APAnastasia L. Panova
Anastasia L. Panova
EPElena V. Privalova
Elena V. Privalova
VLVladimirovich
Vladimirovich
Remote monitoring of patients, including those with chronic heart failure, has been actively used in recent years. Unlike invasive methods, non-invasive methods are not associated with surgical risks and offer a wide range of patient management options such as telemonitoring, virtual visits, emergency department pre-triage, in-hospital telemedicine, telemedicine rehabilitation, psychological support, etc. Previously, remote monitoring required a multidisciplinary medical team to ensure high efficiency, and attempts to use advanced technology to reduce human involvement were often unsuccessful. However, all electronic and telemedicine technologies in healthcare have been dramatically transformed by the COVID-19 pandemic. There is currently a wide variety of remote monitoring methods and technologies. But it is still impossible to clearly assess their effectiveness due to a lack of common standards, inadequate legislation, and regional, social, and economic differences in the availability of these technologies. However, in 2021, remote monitoring was included in the European Society of Cardiology clinical guidelines for the diagnosis and management of acute and chronic heart failure (IIb). This review describes the history of modern remote monitoring methods and the problems they are designed to solve in order to improve outpatient health monitoring for patients with chronic heart failure.

29 May 2025 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Open access
PDF file
EZElena Zheleznykh
Elena Zheleznykh
APAnastasia Panova
Anastasia Panova
AEAleksei Emelianov
Aleksei Emelianov
DKDaria Kutsakina
Daria Kutsakina
ANAndrei Nartov
Andrei Nartov
MKMaria Kozhevnikova
Maria Kozhevnikova
Background: Patients with chronic heart failure (HF) require outpatient monitoring after hospital discharge. The ability to use a smartphone with a personal messaging application may help. Objectives: Tis study aimed to investigate the feasibility of remote monitoring and evaluate its impact on treatment adherence and prognosis in patients with HF. Methods: A total of 100 patients were enrolled in the study: 57 patients in the mHealth group and 43 in the control group. The observation period lasted six months. [...] Abstract Background: Patients with chronic heart failure (HF) require outpatient monitoring after hospital discharge. The ability to use a smartphone with a personal messaging application may help. Objectives: Tis study aimed to investigate the feasibility of remote monitoring and evaluate its impact on treatment adherence and prognosis in patients with HF. Methods: A total of 100 patients were enrolled in the study: 57 patients in the mHealth group and 43 in the control group. The observation period lasted six months.